InvestorsHub Logo
Followers 13
Posts 1546
Boards Moderated 0
Alias Born 06/14/2018

Re: None

Thursday, 08/04/2022 5:02:46 PM

Thursday, August 04, 2022 5:02:46 PM

Post# of 34624
The following from the PR ... " In addition, the FDA has cleared Marker to initiate its study at a dose level of 200 million cells per infusion, versus the dose range of 10-40 million cells per infusion used in the TACTAL study." ..... may be very good as it should results in much better outcomes and much more positive patient responses.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News